Skip to main content
Fig. 4 | Allergy, Asthma & Clinical Immunology

Fig. 4

From: Aberrant localization of FOXJ1 correlates with the disease severity and comorbidities in patients with nasal polyps

Fig. 4

The mRNA expression levels of FOXJ1 between controls and patients with nasal polyps. No significant difference of FOXJ1 mRNA expression levels was found between controls and patients with NPs (n = 77) (a). The FOXJ1 mRNA expression levels were found to be higher in NPs without AR or asthma (n = 32) than control subjects (b). The FOXJ1 mRNA expression levels were significantly downregulation in both NPs with isolated AR (n = 25), and NPs with isolated asthma (n = 20) (c). AR: allergic rhinitis; FOXJ1: forkhead-box J1; NPs: nasal polyps

Back to article page

Allergy, Asthma & Clinical Immunology

ISSN: 1710-1492

Contact us